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Abstract  
Objective: Over 90% of suicide attempters have a psychiatric diagnosis, however twin and family 
studies suggest that the genetic etiology of suicide attempt (SA) is partially distinct from that of the 
psychiatric disorders themselves. Here, we present the largest genome-wide association study 
(GWAS) on suicide attempt using major depressive disorder (MDD), bipolar disorder (BIP) and 
schizophrenia (SCZ) cohorts from the Psychiatric Genomics Consortium. 
 
Method: Samples comprise 1622 suicide attempters and 8786 non-attempters with MDD, 3264 
attempters and 5500 non-attempters with BIP and 1683 attempters and 2946 non-attempters with 
SCZ. SA GWAS were performed by comparing attempters to non-attempters in each disorder followed 
by meta-analyses across disorders. Polygenic risk scoring was used to investigate the genetic 
relationship between SA and the psychiatric disorders.  
  
Results: Three genome-wide significant loci for SA were found: one associated with SA in MDD, one 
in BIP, and one in the meta-analysis of SA in mood disorders.  These associations were not replicated 
in independent mood disorder cohorts from the UK Biobank and iPSYCH. No significant associations 
were found in the meta-analysis of all three disorders. Polygenic risk scores for major depression were 
significantly associated with SA in MDD (R2=0.25%, P=0.0006), BIP (R2=0.24%, P=0.0002) and SCZ 
(R2=0.40%, P=0.0006).  
 
Conclusions: This study provides new information on genetic associations and demonstrates that 
genetic liability for major depression increases risk for suicide attempt across psychiatric disorders. 
Further collaborative efforts to increase sample size hold potential to robustly identify genetic 
associations and gain biological insights into the etiology of suicide attempt.  
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Introduction 
Suicide is a worldwide public health problem with over 800,000 deaths due to suicide each year (1). It 
is the second leading cause of death among young adults and rates of suicide are far exceeded by 
suicide attempts, which occur up to 20 times more frequently (1). This represents a huge personal, 
social and economic burden, with the Centers for Disease Control and Prevention reporting that 
suicide costs the US economy $51 billion per year in healthcare and work-loss related costs (2). These 
stark figures highlight the urgent need for improved prevention and treatment, however progress has 
been hampered by the lack of reliable methods for predicting suicidality and a poor understanding of 
its biological etiology. 
  
Over 90% of suicide attempters or individuals who die by suicide have a psychiatric disorder, 
particularly mood disorders, schizophrenia and substance use disorders (3, 4). Heritability estimates 
of suicidal behavior from twin studies range from 30-55% and twin and family studies suggest that the 
genetic etiology of suicide attempt is partially distinct from that of the psychiatric disorders 
themselves (5, 6). Several genome-wide association studies (GWAS) have been conducted on suicide 
attempt, by comparing attempters versus non-attempters with depression or bipolar disorder, to test 
for genetic variants contributing independently to suicide attempt (7-10). These studies have failed to 
identify any replicable genetic associations, likely due to limited sample sizes that were underpowered 
to detect the genetic effects typical for a single SNP. Other GWAS have examined subjects recruited 
specifically on the basis of suicide attempt, or suicide attempters and non-attempters from 
population-based cohorts, but to date no loci have been robustly implicated (11-14).   
 
Genetic studies have indicated that suicide attempt has a polygenic architecture, as polygenic risk 
scores for suicide attempt have shown modest predictive ability in independent samples and small 
but significant SNP-heritability estimates for suicide attempt have been reported (10, 13, 14). These 
findings are consistent with the presence of small genetic effects that the original GWAS were 
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underpowered to detect at genome-wide significance. In the current study, we present the largest 
GWAS on suicide attempt to date, comparing a total of 6,569 suicide attempters and 17,232 non-
attempters, with major depressive disorder (MDD), bipolar disorder (BIP) or schizophrenia (SCZ) from 
the Psychiatric Genomics Consortium.  
 
 
Method 
Subjects and phenotype definition 
Subjects were drawn from 16 MDD cohorts, 21 BIP cohorts and 9 SCZ cohorts in the Psychiatric 
Genomics Consortium (PGC), where information on suicide attempt (SA) had been collected. Only 
cases affected with psychiatric disorders were included, and all psychiatric disorders were defined 
using structured psychiatric interviews according to international consensus criteria (DSM-IV, ICD-9, 
or ICD-10) (15-17). Supplementary Tables 1-3 summarise the source, inclusion and exclusion criteria 
in each cohort. All subjects were of European ancestry. Items from structured clinical interviews 
provided information on self-harm, suicidal ideation, plans and suicide attempt (Supplementary Table 
4). Lifetime suicide attempt (SA) was defined across cohorts as a deliberate act of self-harm with at 
least some intent to result in death. Individuals who did not endorse suicide attempt were included in 
the non-attempter group and individuals missing information on suicide attempt were excluded. 
Across the MDD, BIP and SCZ datasets, there were a total of 6,569 suicide attempters and 17,232 non-
attempters (Table 1). All subjects gave written informed consent to participate in the source studies.  
  
Genotyping, quality control and imputation  
Cohorts were genotyped following their local protocols, after which standardised quality control and 
imputation were performed centrally using the PGC ‘Ricopili’ pipeline 
(https://sites.google.com/a/broadinstitute.org/ricopili/), for each cohort separately. These 
procedures have been described in detail previously (18-20). Briefly, the quality control parameters 
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for retaining SNPs and subjects were: SNP missingness < 0.05 (before sample removal), subject 
missingness < 0.02, autosomal heterozygosity deviation (Fhet < 0.2), SNP missingness < 0.02 (after 
sample removal), difference in SNP missingness between psychiatric cases and healthy controls < 0.02, 
SNP Hardy-Weinberg equilibrium (P > 10−10 in psychiatric cases) and minor allele frequency ≥ 0.01. 
Genotype imputation was performed using the pre-phasing/ imputation stepwise approach 
implemented in IMPUTE2/ SHAPEIT (chunk size of 3 Mb and default parameters) to the 1000 Genomes 
Project reference panel (21-23). SNPs with an imputation INFO-score < 0.6 were excluded. The 
numbers of SNPs analysed were 8482392, 8807006 and 8814543 in the MDD, BIP, and SCZ datasets 
respectively.  
 
Statistical analysis 
GWAS on suicide attempt were performed using PLINK 1.9 by comparing imputed marker dosages 
under an additive logistic regression model between suicide attempters and non-attempters in each 
cohort separately (24). The first five principal components (PCs), generated using EIGENSTRAT were 
used as covariates in all GWAS to control for population stratification (25). There was no evidence of 
stratification artifacts or uncontrolled test statistic inflation in the results from any cohort (e.g. λGC was 
0.87 - 1.01). Within each psychiatric disorder, meta-analysis was performed using an inverse variance-
weighted fixed effects model in METAL, to obtain GWAS results for suicide attempt in MDD, suicide 
attempt in BIP and suicide attempt in SCZ (26). In order to increase sample size, a fixed effects meta-
analysis on suicide attempt was conducted across all three psychiatric disorders. To investigate 
depressive suicide attempts, a meta-analysis across MDD and BIP was performed and a meta-analysis 
across BIP and SCZ was used to investigate psychotic suicide attempts.  
 
Polygenic risk scoring was used to dissect the genetic relationship between suicide attempt and the 
psychiatric disorders and to test for overlap in the genetic etiology of suicide attempt in MDD, BIP and 
SCZ. Supplementary Table 5 summarises the polygenic scoring analyses conducted, showing the 
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discovery and test datasets used to investigate these hypotheses. First, PRS for BIP, major depression 
and SCZ were used to investigate whether suicide attempters and non-attempters differ in genetic 
liability for the psychiatric disorder they are affected by. To ensure no overlap between the discovery 
and test datasets, PRS for psychiatric disorders were generated using PGC cohorts not included in the 
suicide attempt analyses (18-20). The discovery GWAS for BIP consisted of 8,711 BIP cases and 15,283 
controls, and for SCZ included 25,756 SCZ cases and 35,686 controls. The discovery GWAS for major 
depression is a recent meta-analysis of PGC MDD cohorts and samples from deCODE, GERA, iPSYCH, 
Generation Scotland and UK Biobank (18). The phenotype analysed included clinically defined MDD 
cases as well as self-reported MDD symptoms or treatment and thus is referred to as ‘major 
depression’. This GWAS had approximately 59,000 cases and 112,000 controls. The PRS for BIP, major 
depression and SCZ were tested for association with suicide attempter versus non-attempter status 
in the same disorder. Second, based on the results of these analyses, PRS for major depression were 
also tested for association with suicide attempt in BIP and SCZ. Third, in order to investigate genetic 
overlap in suicide attempt across psychiatric disorders, the results of the three GWAS on suicide 
attempt (SA in MDD, SA in BIP and SA in SCZ) were used in turn as discovery studies and PRS for suicide 
attempt were tested for association with SA in the other disorders.  
 
PRSice software was used to generate polygenic risk scores (PRS), according to standard protocol (27). 
Briefly, the GWAS results from each discovery study were pruned for linkage disequilibrium (LD) using 
the P value informed clumping method and subsets of SNPs were selected from the results at nine 
increasingly liberal P value thresholds. Sets of alleles, weighted by their log odds ratios (OR) from the 
discovery GWAS, were summed into PRS for each individual in the test datasets. PRS were investigated 
for association with suicide attempt in the test dataset using a logistic regression model including five 
PCs and a covariate for each cohort in the test dataset. The amount of variance explained by the PRS 
(R2) is presented on the liability scale, which accounts for the proportion of cases in test dataset (28).  
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The Bonferroni corrected significance threshold for the polygenic scoring analyses is 0.006, adjusting 
for eight independent tests (Supplementary Table 5).  Full details of the PRS calculations, discovery 
and test datasets are available in the Supplementary Materials.  
 
The variance in suicide attempt explained by common SNPs (SNP-heritability, ℎ𝑆𝑁𝑃
2 ) was assessed 
using genomic-relatedness-based restricted maximum-likelihood (GREML), implemented in GCTA 
software (29). The SNP probabilities were converted to best-guess data with a genotype call 
probability cut-off of 0.8. HapMap 3 SNPs with an INFO score ≥ 0.6 were used to calculate the genetic 
relatedness matrix (GRM) using PLINK 1.9, including individuals with relatedness < 0.05 (24). Ancestry 
informative principal components were calculated using GCTA (29). The GRM was based on a total of 
1166347 SNPs in the MDD dataset, 1172705 SNPs in the BIP dataset and 1143070 SNPs in the SCZ 
dataset. Covariates included 20 PCs calculated using GCTA (because GRM-based analyses are more 
sensitive to population stratification than polygenic scoring analyses) and a covariate for each cohort 
within a disorder. The ℎ𝑆𝑁𝑃
2  of SA in each psychiatric disorder was calculated using GCTA (29).   
 
Power calculations 
The Genetic Power Calculator was used to determine the power to detect associations at genome-
wide significance (P < 5 x 10-8), for the meta-analysis of 6,569 suicide attempters and 17,232 non-
attempters across the three psychiatric disorders (30). This analysis had 78% power to detect an allele 
with frequency 0.2 and effect size 1.1 at genome-wide significance. From the GCTA-GREML power 
calculator, the power to detect a ℎ𝑆𝑁𝑃
2  of 20% (approximately half the twin heritability estimate) for 
suicide attempt was 81%, 92% and 43% in the MDD, BIP and SCZ datasets respectively (31). The 
statistical power of polygenic risk scoring was calculated using AVENGEME software (32, 33). The 
power of the PRS for the psychiatric disorders to predict SA in same disorder was 51% in BIP, 93% in 
MDD and 78% in SCZ, given the ℎ𝑆𝑁𝑃
2  for these psychiatric disorders calculated from the summary 
statistics (20%, 10% and 25% respectively) and hypothesizing a genetic correlation of 0.5 between the 
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psychiatric disorder and suicide attempt. Given a ℎ𝑆𝑁𝑃
2  of 20% for suicide attempt, the power of 
polygenic risk scores for suicide attempt to detect a significant difference between attempters and 
non-attempters in the test datasets ranged from 32-64%. The significance threshold for all polygenic 
risk scoring power calculations was 0.006.  
 
Replication  
Genome-wide significant associations with suicide attempt were tested for replication in two 
independent mood disorder cohorts from the UK Biobank and iPSYCH. The UK Biobank is a population-
based prospective study of 501,726 individuals, recruited at 23 centres across the United Kingdom 
(34). Extensive phenotypic data are available for UK Biobank participants from health records and 
questionnaires, including an online follow-up questionnaire focusing on mental health (Mental Health 
Questionnaire, MHQ [Resource 22 on http://biobank.ctsu.ox.ac.uk]). Participants were classified as 
having a mood disorder if they either self-reported a professional diagnosis of depression or bipolar 
disorder as part of the MHQ [UK Biobank field 20544, responses 10 or 11] or if they met criteria for 
depression or bipolar disorder on MHQ questions derived from the Composite International 
Diagnostic Interview (CIDI). Suicide attempters with mood disorders (n=2,149, 91% with depression) 
were defined as those who answered yes to the question “Have you ever harmed yourself with the 
intention to end your life?” [UK Biobank field f20483]. Non-attempters with mood disorders were 
defined as those who reported no self-harm on the MHQ (n=35,912). Genetic associations with suicide 
attempt were tested by comparing suicide attempters versus non-attempters with mood disorders 
using BGenie v.1.2 (35), covarying for six PCs and factors capturing site of recruitment and genotyping 
batch. Full details of the genetic quality control, imputation and mood disorder criteria are available 
in the Supplementary Materials.  
 
In the iPSYCH cohort, individuals with mood disorders were identified based on ICD-10 codes (F30-
F39) from the Danish Psychiatric Central Research Register and the National Registry of Patients, both 
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complete until December 31, 2016 (36). Suicide attempters with mood disorders (n=4,943, 94% with 
MDD) were defined as those with diagnoses of suicide attempt (ICD-10: X60-X84, equivalent to 
intentional self-harm), those with suicide attempt indicated as ‘reason for contact’, and with a main 
diagnosis of poisoning (ICD-10: T39, T42, T43, and T58) or those with a diagnosis in the ICD-10: F 
chapter as main diagnosis and report of poisoning by drugs or other substances (ICD-10: T36–T50, 
T52–T60) or injuries to hand, wrist, and forearm (ICD-10: S51, S55, S59, S61, S65, S69). Individuals who 
died by suicide according to the Cause of Death Register were also included in the suicide attempter 
group. Non-attempters were defined as mood disorder cases not fulfilling any of these criteria 
(n=15,849). Genetic associations with suicide attempt were tested by comparing suicide attempters 
versus non-attempters with mood disorders, including 10 PCs and genotyping batch as covariates. Full 
details of quality control in the iPSYCH cohort are included in the Supplementary Materials.  
 
 
Results 
Sample characteristics 
The proportion of psychiatric disorder cases reporting suicide attempt ranged from 16% in MDD to 
36-37% in bipolar disorder and schizophrenia (Table 1).  For each disorder, there was a higher 
proportion of females in the suicide attempters than the non-attempters. Table 1 shows the number 
and proportion of suicide attempters and non-attempters within each psychiatric disorder. The 
numbers in the individual PGC cohorts are shown in Supplementary Tables 6-8. 
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Genome-wide association studies 
A GWAS of suicide attempters versus non-attempters was performed in the MDD, BIP and SCZ 
datasets separately. In the analysis of suicide attempt in MDD, one SNP reached genome-wide 
significance: rs45593736, P = 2.61 x 10-8, OR A allele = 2.38 (Table 2). This SNP is in an intron of the 
ARL5B (ADP-Ribosylation Factor-Like 5B) gene, and the A allele has a frequency of 0.02. In the GWAS 
of suicide attempt in BIP, an insertion-deletion polymorphism on chromosome 4 met genome-wide 
significance: chr4_23273116_D, P = 1.15x10-8, OR for the deletion = 1.29 (Table 2). This is an intronic 
variant in the non-coding RNA LOC105374524. In the analysis of suicide attempt in SCZ, there were no 
SNPs reaching genome-wide significance, but this analysis had the smallest total sample size.  
 
Meta-analysis of the GWAS results for suicide attempt across all three disorders produced no genome-
wide significant results (Supplementary Figure 4). In a meta-analysis of suicide attempt in mood 
disorders (MDD and BIP), there were 10 genome-wide significant SNPs from two independent 
genomic regions (Table 2, Figure 1). The most significant association was rs138689899 on 
chromosome 2, P = 2.50 x 10-8, OR T allele = 1.75. This is an intergenic SNP that lies between the IWS1 
and MYO7B genes. The other significant locus was on chromosome 4 in LOC105374524, as found in 
the BIP SA analysis. The most significant SNP was rs28591567 (P = 3.11 x 10-8, OR G allele = 1.19, 
frequency G allele = 0.22), in high LD (R2= 0.83) with the insertion-deletion polymorphism identified 
in SA in BIP (Table 2). Weak evidence for association was found in MDD (rs28591567, P = 0.03, OR 
allele G allele = 1.11); the locus was not associated with SA in schizophrenia (P = 0.67). No significant 
associations were identified in the meta-analysis between SA in BIP and SCZ (Supplementary Figure 
5). Manhattan plots and tables of the top results from all GWAS are in the Supplementary Materials 
(Supplementary Figures 1-5, Supplementary Tables 9-14). 
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Replication 
SNPs from the three genome-wide significant loci for suicide attempt in the discovery phase were 
tested for replication in independent mood disorder cohorts from the UK Biobank and iPSYCH. None 
of these loci showed association with suicide attempt in mood disorders in either study (minimum P 
value 0.22; Table 2, Full results shown in Supplementary Table 15).   
 
Polygenic risk scoring and SNP-heritability  
Polygenic risk scoring was performed to investigate the genetic etiology of suicide attempt in MDD, 
BIP and SCZ using scores from GWAS on psychiatric disorders and the SA GWAS conducted here. PRS 
for major depression were significantly associated with suicide attempt in all three disorders (MDD - 
maximum variance explained on the liability scale (R2) = 0.25%, P = 0.0006; BIP - R2 = 0.24%, P = 0.0002; 
SCZ - R2 = 0.40%, P = 0.0006; Figure 2).  The PRS for BIP did not differ between suicide attempters and 
non-attempters with BIP, while PRS for schizophrenia were significantly lower in suicide attempters 
with schizophrenia compared with non-attempters (R2 = 0.42%, P = 0.0004, Supplementary Figure 6).  
 
The SNP heritability (ℎ𝑆𝑁𝑃
2 ) of suicide attempt in each psychiatric disorder was estimated using GREML. 
The ℎ𝑆𝑁𝑃
2  estimate of suicide attempt in MDD was 0.03 (SE = 0.03, P = 0.19), in BIP was 0.02 (SE = 0.03, 
P = 0.25) and in SCZ was 0.10 (SE = 0.07, P = 0.06). None of these ℎ𝑆𝑁𝑃
2  estimates were significantly 
different from zero.  Using these SA GWAS as discovery studies, the polygenic risk scores for SA in one 
psychiatric disorder were not associated with suicide attempt in another disorder (Supplementary 
Figure 7). 
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Discussion 
This GWAS on suicide attempt is the largest performed to date, combining samples of suicide 
attempters and non-attempters across three major psychiatric disorders and 46 individual cohorts 
from the Psychiatric Genomics Consortium. Three independent loci were associated with suicide 
attempt in the discovery phase. The strongest support was for the chromosome 4 locus in 
LOC105374524, a non-coding RNA, located approximately 500Kb downstream of the GBA3 
(Glucosylceramidase Beta 3) gene and upstream of PPARGC1A, which is a transcriptional coactivator 
that regulates the genes involved in energy metabolism. This region reached genome-wide 
significance in the GWAS of suicide attempt in bipolar disorder and the association strengthened in 
the meta-analysis of suicide attempt in mood disorders. Despite the support for this locus in the 
discovery phase, the association was not replicated in large independent mood disorder cohorts from 
the UK Biobank and iPSYCH. One possible explanation for this lack of replication is that over 90% of 
suicide attempters in the replication cohorts had a depression diagnosis, while in the discovery PGC 
studies, this locus had strongest effect in BIP. In addition, there may be heterogeneity in the definition 
of suicide attempt, which in the discovery samples was based on psychiatric interviews and in the 
replication samples was based on self-report questionnaires and hospital records. For the other two 
loci reaching genome-wide significance for suicide attempt in the discovery phase, statistical power 
for replication was low, given the effect allele frequency of 2% at each locus.  
 
The within-case analysis strategy utilised in this GWAS was designed to detect associations specific for 
suicide attempt and was informed by twin and family studies which consistently indicate a genetic 
component of SA which is partially distinct from that of the psychiatric disorders themselves (5, 6). 
The LOC105374524 association with suicide attempt in mood disorders reported here has not been 
implicated in GWAS of major depression, BIP or SCZ, indicating its specificity for suicide attempt, and 
providing support for a partially distinct genetic etiology (18-20, 37, 38).  
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Through polygenic scoring analyses we showed that genetic liability for major depression increases 
risk for suicide attempt, as suicide attempters with MDD, BIP and SCZ all had higher PRS for major 
depression than non-attempters. Clinical studies are consistent with these findings, with increased 
depressive symptoms in bipolar disorder and the presence of depressive symptoms in schizophrenia 
being risk factors for suicide attempt (39, 40). Indeed, depressive symptom-based factor scores 
generated from clinical symptom data available for PGC  schizophrenia cases, were significantly higher 
in suicide attempters than non-attempters (Supplementary Materials) (41). Our results suggest that 
the genetic etiology of SA may be partially unique and partially shared with major depression, and this 
is consistent with recent findings showing high genetic correlation between these two phenotypes 
(13). Given the widespread pleiotropy between psychiatric disorders, some genetic overlap with other 
disorders is expected (42). This study is the first to show that across disorders, suicide attempters carry 
a greater burden of depression risk alleles rather than simply a higher genetic liability for the 
psychiatric disorder they are affected by. The finding that non-attempters with schizophrenia have 
higher PRS for schizophrenia while suicide attempters have higher PRS for depression, demonstrates 
the genetic heterogeneity that exists within psychiatric cases. In previous studies major depression 
PRS have been shown to explain approximately 2% of variance in depression case-control status, 
compared with up to 0.4% of variance in suicide attempter status reported here (18).  Despite the 
smaller variance explained, it is promising that PRS can now be used within psychiatric cases, to 
distinguish between individuals with different symptom profiles or comorbidities.   
 
The SNP-heritability estimates for suicide attempt in each disorder were not significantly different 
from zero and while several twin studies have reported that suicide attempt is moderately heritable, 
one study found that after adjusting for psychiatric disorders, the heritability decreased from 30% to 
17% (5, 43). Given estimated SNP-heritabilities are generally much lower than twin heritabilities, our 
samples were underpowered to identify this level of genetic contribution.  If this is a more accurate 
estimate of the independent genetic contribution to suicide attempt, then substantial increases in 
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sample size will be required to fully interrogate the genetic etiology of suicide attempt. Still, the 
present study is the first consortium-based GWAS on suicide attempt and makes significant progress 
in increasing numbers by combining samples across clinical cohorts. Further collaborative efforts to 
amass samples on an even larger scale will be essential to achieve the success seen in GWAS of other 
psychiatric disorders. Data from population biobanks are now widely available and leveraging these 
to conduct meta-analyses could rapidly increase statistical power. GWAS comparing suicide 
attempters versus healthy controls may provide a complementary approach by prioritising loci for 
follow-up in case-only studies, which should be expanded beyond studies of mood disorders and 
schizophrenia to also include existing cohorts for other disorders where suicide attempt is prevalent. 
The results of GWAS now robustly link hundreds of genetic loci to psychiatric disorders and provide 
additional opportunities to disentangle genetic effects on suicide attempt from the disorders 
themselves.   
 
 One strength of this study is that samples of suicide attempters have been successfully combined 
across many individual clinical cohorts. All 46 datasets were processed centrally using the same quality 
control, imputation and analysis pipeline. Suicide attempt and non-attempt were defined using items 
from structured psychiatric interviews. These items vary by interview, which may be considered a 
limitation, although we note that the psychiatric interview or type of item used did not result in 
heterogeneity in the prevalence of suicide attempt across these cohorts (Supplementary Materials). 
Since subjects were not ascertained primarily for suicide attempt, detailed information such as the 
number of suicide attempts, medical consequences or medication is not available for all participants. 
This study focused on lifetime suicide attempt to maximize sample size, but some cases who were 
non-attempters at the time of recruitment may later have attempted suicide.  
 
Of all the psychiatric phenotypes, suicidality remains especially challenging to predict and assess and 
there is an urgent need to better understand its etiology. As seen in GWAS of other psychiatric 
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disorders, the number of genetic associations is expected to accumulate with increased sample size 
and can provide invaluable biological insights. Our novel finding that genetic liability for major 
depression increases risk of suicide attempt in MDD, BIP, and SCZ provides a possible starting point 
for predictive modelling and preventative strategies. The ultimate goal of genetic studies on suicide 
attempt is to translate these statistical associations into biological mechanisms and much-needed 
treatments and preventions for suicidality, in order to reduce its burden on patients, families and 
healthcare systems. 
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Tables and Figures 
Table 1: Sample characteristics of discovery and replication cohorts 
Phase Sample 
N 
cohorts 
N Suicide attempters (%)  N Non-attempters (%) 
N Female         N Female  
Suicide attempters (%) Non-attempters (%) 
Discovery 
PGC Major depressive disorder 16 1622 (16%) 8786 (84%) 1155 (71%) 5808 (66%) 
PGC Bipolar disorder 21 3264 (37%) 5500 (63%) 2097 (66%) 2971 (56%) 
PGC Schizophrenia 9 1683 (36%) 2946 (64%) 660 (39%) 924 (31%) 
Total 46 6569 (28%) 17232 (72%) 3912 (60%) 9703 (56%) 
Replication 
UK Biobank (mood disorders*) 1 2149   (6%) 35912 (94%)  1521 (71%)  24039 (67%) 
iPSYCH (mood disorders*) 1 4943 (24%) 15849 (76%)  3694 (75%)  10276 (65%) 
PGC, Psychiatric Genomics Consortium *All samples in the UK Biobank and iPSYCH replication cohorts had depression or bipolar disorder. 
 
 
 
Table 2: Genome-wide significant loci for suicide attempt showing the most significant variant from each genomic region 
Discovery 
Dataset 
Variant CHR BP 
Tested 
allele 
Allele 
freq 
INFO 
score 
P value 
OR            
(C.I.) 
Direction in each 
cohort 
Genes                                    
(distance from SNP 
in Kb) 
P value  
UK Biobank 
replication 
cohort^ 
P value 
iPSYCH        
replication 
cohort^ 
MDD rs45593736 10 18954937 A 0.02 0.89 2.61E-08 
2.38             
(1.75-3.23) 
?++++-++?+-
?++++ 
ARL5B (intronic) 0.985 0.776 
BIP chr4_23273116_D* 4 23273116 D 0.20 0.91 1.15E-08 
1.29         
(1.18-1.41) 
++++++++++++++-
-+++++ 
LOC105374524    
Mood 
disorders  
rs138689899 2 128288162 T 0.02 0.91 2.50E-08 
1.75           
(1.44-2.14) 
++ 
IWS1(3.7),                    
MYO7B (107.1) 
0.677 0.228 
Mood 
disorders  
rs28591567* 4 23253912 G 0.22 0.95 3.11E-08 
1.19           
(1.12-1.27) 
++ LOC105374524 0.663 0.521 
CHR, chromosome; BP, basepair position; freq, frequency; OR, odds ratio; CI, confidence interval; MDD, major depressive disorder; BIP, bipolar disorder.    
*chr4_23273116_D and rs28591567 LD R2 = 0.83 ^Full details of replication results are in Supplementary Materials 
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Figure 1: Manhattan plot for meta-analysis of suicide attempt in mood disorders. The red line 
shows the genome-wide significance threshold (P < 5 x 10-8). SNPs in green are in linkage 
disequilibrium with the index SNPs (diamonds).  
 
 
Figure 2: Polygenic risk scores for major depression are higher in suicide attempters versus non-
attempters with bipolar disorder, major depressive disorder and schizophrenia. The x-axis shows the 
P value threshold used to select SNPs from the discovery GWAS. The y-axis shows the percentage 
variance explained on the liability scale. P values of association between polygenic scores and suicide 
attempt are shown above each bar. 
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